KG&L Capital Management LLC Has $4.05 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

KG&L Capital Management LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 10.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 5,243 shares of the company’s stock after acquiring an additional 510 shares during the quarter. Eli Lilly and Company makes up about 1.3% of KG&L Capital Management LLC’s portfolio, making the stock its 17th largest holding. KG&L Capital Management LLC’s holdings in Eli Lilly and Company were worth $4,048,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the business. Marietta Wealth Management LLC raised its position in shares of Eli Lilly and Company by 0.5% during the fourth quarter. Marietta Wealth Management LLC now owns 12,884 shares of the company’s stock worth $9,946,000 after acquiring an additional 60 shares during the last quarter. Concord Wealth Partners increased its position in Eli Lilly and Company by 6.8% during the 4th quarter. Concord Wealth Partners now owns 5,413 shares of the company’s stock valued at $4,179,000 after purchasing an additional 346 shares during the period. Concord Asset Management LLC VA raised its holdings in Eli Lilly and Company by 8.3% during the 4th quarter. Concord Asset Management LLC VA now owns 4,917 shares of the company’s stock worth $3,796,000 after purchasing an additional 377 shares during the last quarter. Chicago Partners Investment Group LLC lifted its position in shares of Eli Lilly and Company by 2.0% in the 4th quarter. Chicago Partners Investment Group LLC now owns 18,897 shares of the company’s stock worth $14,876,000 after purchasing an additional 369 shares during the period. Finally, Waldron Private Wealth LLC boosted its stake in shares of Eli Lilly and Company by 0.5% in the 4th quarter. Waldron Private Wealth LLC now owns 14,113 shares of the company’s stock valued at $10,895,000 after purchasing an additional 74 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent analyst reports. Wells Fargo & Company dropped their target price on shares of Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. Bank of America reissued a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Citigroup decreased their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Barclays cut their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. Finally, Wolfe Research began coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price objective for the company. Five investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $997.22.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $811.61 on Monday. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The stock has a market cap of $770.48 billion, a PE ratio of 87.74, a price-to-earnings-growth ratio of 1.71 and a beta of 0.41. The stock’s fifty day simple moving average is $783.56 and its two-hundred day simple moving average is $844.18. Eli Lilly and Company has a 1-year low of $637.00 and a 1-year high of $972.53.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, February 14th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a yield of 0.74%. Eli Lilly and Company’s payout ratio is 56.22%.

Eli Lilly and Company declared that its board has authorized a stock buyback program on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 2% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling

In other news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. The trade was a 14.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.13% of the stock is owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.